伊布替尼治疗复发/难治性慢性淋巴细胞白血病的老年患者：法国71例患者的真实世界经验：法国创新白血病组织（FILO）组的一项研究 - Suppr | 超能文献

相似文献

1

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.伊布替尼治疗复发/难治性慢性淋巴细胞白血病的老年患者：法国71例患者的真实世界经验：法国创新白血病组织（FILO）组的一项研究

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29.

2

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。

Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.

3

What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？依鲁替尼应作为标准一线治疗。

Clin Adv Hematol Oncol. 2016 May;14(5):330-3.

4

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.RESONATE 最终分析：先前接受治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者接受伊布替尼治疗的最长六年随访结果。

Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.

5

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.伊布替尼在法国复发/难治性慢性淋巴细胞白血病中的真实世界结果：428例患者的大型系列早期结果

Am J Hematol. 2017 Aug;92(8):E166-E168. doi: 10.1002/ajh.24773. Epub 2017 May 30.

6

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.一线伊布替尼治疗老年慢性淋巴细胞白血病患者的持续疗效和详细临床随访：RESONATE-2 扩展阶段 3 的结果。

Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.

7

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.伊布替尼治疗慢性淋巴细胞白血病患者完全缓解的预后因素：2 项临床试验的汇总分析。

JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.

8

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。

Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.

9

What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？化学免疫疗法应作为标准一线治疗。

Clin Adv Hematol Oncol. 2016 May;14(5):336-8.

10

Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.加拿大某中心接受依鲁替尼治疗的复发或难治性慢性淋巴细胞白血病患者的剂量及治疗结果描述性分析。

Curr Oncol. 2019 Oct;26(5):e610-e617. doi: 10.3747/co.26.4957. Epub 2019 Oct 1.

引用本文的文献

1

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.3306例在临床试验之外接受依鲁替尼治疗的复发/难治性慢性淋巴细胞白血病患者的结局及预后因素：一项全国性研究

Hemasphere. 2024 Oct 8;8(10):e70017. doi: 10.1002/hem3.70017. eCollection 2024 Oct.

2

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.在日本，ibrutinib 治疗复发/难治性 CLL 和 SLL 的疗效和安全性：一项上市后监测。

J Clin Exp Hematop. 2022 Sep 28;62(3):136-146. doi: 10.3960/jslrt.22002. Epub 2022 Jul 12.

3